{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:41:31Z","timestamp":1793450491285,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020704","name":"Instituto de Investigaciones Biom\u00e9dicas, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006087","name":"National Autonomous University of Mexico Directorate General of Academic Staff Affairs","doi-asserted-by":"publisher","award":["IN212323"],"award-info":[{"award-number":["IN212323"]}],"id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.molimm.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T05:35:07Z","timestamp":1749274507000},"page":"51-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["DNA vaccination combined with immune checkpoint inhibition eradicates tumors, inducing life-long immunity against breast cancer in mice"],"prefix":"10.1016","volume":"184","author":[{"given":"Allan No\u00e9","family":"Dom\u00ednguez-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Alejandro","family":"Esquivel-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mart\u00ednez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braulio A.","family":"Mart\u00ednez-Zarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu\u00e9","family":"Odales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Abraham-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Maruri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Villegas-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goar","family":"Gevorkian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Manoutcharian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.molimm.2025.06.003_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-017-2111-y","article-title":"Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model","volume":"67","author":"Allen","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molimm.2025.06.003_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-024-00923-w","article-title":"Targeting chromosomal instability in patients with cancer","volume":"21","author":"Al-Rawi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molimm.2025.06.003_bib3","article-title":"Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"2024","author":"Baharom","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.molimm.2025.06.003_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/104454901750219099","article-title":"Intraspleen DNA inoculation elicits protective cellular immune responses","volume":"20","author":"Cano","year":"2001","journal-title":"DNA Cell Biol."},{"issue":"17","key":"10.1016\/j.molimm.2025.06.003_bib5","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.3390\/ijms231710131","article-title":"Sources of cancer neoantigens beyond single-nucleotide variants","volume":"23","author":"Capietto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.molimm.2025.06.003_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/antib13020046","article-title":"Targeting neoantigens in cancer: possibilities and opportunities in breast cancer","volume":"13","author":"Chaudhry","year":"2024","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.molimm.2025.06.003_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-022-02402-5","article-title":"Linear DNA amplicons as a novel cancer vaccine strategy","volume":"41","author":"Conforti","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10549-021-06459-2","article-title":"Breast cancer vaccines for treatment and prevention","volume":"191","author":"Disis","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.molimm.2025.06.003_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.13233","article-title":"Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes","volume":"161","author":"Dom\u00ednguez-Romero","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.molimm.2025.06.003_bib10","doi-asserted-by":"crossref","first-page":"a028829","DOI":"10.1101\/cshperspect.a028829","article-title":"Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: nothing new in spite of the name","volume":"10","author":"Finn","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molimm.2025.06.003_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102383","article-title":"The current clinical landscape of personalized cancer vaccines","volume":"106","author":"Fritah","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.molimm.2025.06.003_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","article-title":"Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours","volume":"618","author":"Gavish","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2025.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886683","article-title":"Identification of highly cross-reactive mimotopes for a public T cell response in murine melanoma","volume":"13","author":"Grace","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1158\/2326-6066.CIR-21-0332","article-title":"An In Vivo screen to identify short peptide mimotopes with enhanced antitumor immunogenicity","volume":"10","author":"He","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molimm.2025.06.003_bib16","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"2024","author":"Huber","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.molimm.2025.06.003_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"7620","key":"10.1016\/j.molimm.2025.06.003_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2025.06.003_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41591-023-02230-w","article-title":"Evolutionary characterization of lung adenocarcinoma morphology in TRACERx","volume":"29","author":"Karasaki","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.molimm.2025.06.003_bib21","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","article-title":"A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features","volume":"30","author":"Klughammer","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.molimm.2025.06.003_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41551-024-01194-7","article-title":"Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells","volume":"8","author":"Lee","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.molimm.2025.06.003_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-013-1516-5","article-title":"Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors","volume":"63","author":"Lennerz","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molimm.2025.06.003_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2003","journal-title":"JAMA Oncol."},{"issue":"6583","key":"10.1016\/j.molimm.2025.06.003_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.abl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.molimm.2025.06.003_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","article-title":"Challenges in neoantigen-directed therapeutics","volume":"41","author":"Lybaert","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molimm.2025.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101254","article-title":"Are we getting closer to a successful neoantigen cancer vaccine?","volume":"96","author":"Manoutcharian","year":"2024","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.molimm.2025.06.003_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molimm.2023.03.019","article-title":"Tumor antigen-unbiased variable epitope library contains mimotopes with antitumor effect in a mouse model of breast cancer","volume":"57","author":"Mart\u00ednez-Cort\u00e9s","year":"2023","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2025.06.003_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molimm.2021.08.013","article-title":"Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA\/iLRP) using variable epitope libraries tested in an aggressive breast cancer model","volume":"139","author":"Mart\u00ednez-Cort\u00e9s","year":"2021","journal-title":"Mol. Immunol."},{"issue":"7957","key":"10.1016\/j.molimm.2025.06.003_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","article-title":"Genomic-transcriptomic evolution in lung cancer and metastasis","volume":"616","author":"Mart\u00ednez-Ruiz","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molimm.2025.06.003_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002927","article-title":"Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma","volume":"10","author":"Mohsen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molimm.2025.06.003_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223331","article-title":"Immunological analysis of hybrid neoantigen peptide encompassing class I\/II neoepitope-pulsed dendritic cell vaccine","volume":"14","author":"Morisaki","year":"2023","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.molimm.2025.06.003_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103730118","article-title":"Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice","volume":"118","author":"Nakajima","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.molimm.2025.06.003_bib34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"9","author":"Niknafs","year":"2023","journal-title":"Nat. Med."},{"issue":"33","key":"10.1016\/j.molimm.2025.06.003_bib35","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1016\/j.vaccine.2022.06.062","article-title":"Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer","volume":"40","author":"Odales","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.06.003_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.molimm.2025.06.003_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.vaccine.2004.08.007","article-title":"Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin","volume":"23","author":"Otto","year":"2005","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.molimm.2025.06.003_bib38","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1080\/21645515.2020.1754691","article-title":"Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer","volume":"16","author":"Pack","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"7","key":"10.1016\/j.molimm.2025.06.003_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molimm.2025.06.003_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12865-020-00350-3","article-title":"Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model","volume":"21","author":"Peterson","year":"2020","journal-title":"BMC Immunol."},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting tumor heterogeneity with neoantigen-based cancer vaccines","volume":"4","author":"Pounraj","year":"2024","journal-title":"Cancer Res."},{"issue":"7953","key":"10.1016\/j.molimm.2025.06.003_bib42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy","volume":"615","author":"Puig-Saus","year":"2023","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.molimm.2025.06.003_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202409590","article-title":"A biomimetic autophagosomes-based nanovaccine boosts anticancer immunity","volume":"36","author":"Qu","year":"2024","journal-title":"Adv. Mater."},{"issue":"4","key":"10.1016\/j.molimm.2025.06.003_bib44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.molimm.2025.06.003_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molimm.2025.06.003_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-022-00433-9","article-title":"Neoantigen cancer vaccine augments anti-CTLA-4 efficacy","volume":"7","author":"Salvatori","year":"2022","journal-title":"NPJ Vaccin."},{"issue":"7","key":"10.1016\/j.molimm.2025.06.003_bib47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molimm.2025.06.003_bib48","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.molimm.2025.06.003_bib49","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1080\/21645515.2016.1191718","article-title":"Antigenic variability: obstacles on the road to vaccines against traditionally difficult targets","volume":"12","author":"Serv\u00edn-Blanco","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.molimm.2025.06.003_bib50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/biom14040503","article-title":"Recent findings on therapeutic cancer vaccines: an updated review","volume":"14","author":"Sheikhlary","year":"2024","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.molimm.2025.06.003_bib51","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/ph15081017","article-title":"mRNA-loaded lipid nanoparticles targeting immune cells in the spleen for use as cancer vaccines","volume":"15","author":"Shimosakai","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007815","article-title":"Advances and challenges in cancer immunoprevention and immune interception","volume":"12","author":"Stanton","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molimm.2025.06.003_bib53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/bs.ircmb.2024.05.001","article-title":"DNA damage response and neoantigens: a favorable target for triple-negative breast cancer immunotherapy and vaccine development","volume":"389","author":"Subbarayan","year":"2024","journal-title":"Int. Rev. Cell. Mol. Biol."},{"issue":"436","key":"10.1016\/j.molimm.2025.06.003_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"38","key":"10.1016\/j.molimm.2025.06.003_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado6491","article-title":"Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes","volume":"10","author":"Tokita","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molimm.2025.06.003_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1479-5876-6-24","article-title":"Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer","volume":"6","author":"Tsuruma","year":"2008","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.molimm.2025.06.003_bib57","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/vaccines13030246","article-title":"Type I interferon modulates the function of Ly6C high-expressing na\u00efve CD8+ T cells to promote an antitumor response","volume":"13","author":"Tu","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.molimm.2025.06.003_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101292","article-title":"Vaccines for breast cancer prevention: are we there yet?","volume":"98","author":"Vinayak","year":"2024","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.molimm.2025.06.003_bib59","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"ACT IV trial investigators, Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molimm.2025.06.003_bib60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/cancers14020448","article-title":"Identification of tumor antigens and immune subtypes for the development of mRNA vaccines and individualized immunotherapy in soft tissue sarcoma","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.molimm.2025.06.003_bib61","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216836","article-title":"Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma","volume":"15","author":"Wu","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molimm.2025.06.003_bib62","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.molimm.2025.06.003_bib63","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/s41590-024-01932-8","article-title":"Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation","volume":"25","author":"Zhang","year":"2024","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2025.06.003_bib64","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1038\/s41467-024-52139-2","article-title":"Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:24:29Z","timestamp":1762248269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589025001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"alternative-id":["S0161589025001531"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2025.06.003","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA vaccination combined with immune checkpoint inhibition eradicates tumors, inducing life-long immunity against breast cancer in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}